<DOC>
	<DOCNO>NCT01867996</DOCNO>
	<brief_summary>This randomize single sequence open label study . This study design determine chronic dose efavirenz ( EFZ ) effect pharmacokinetics ( PK ) intravenously-administered retosiban healthy volunteer . The study consist screen ( 28 day ) , treatment ( 1 dose session ) follow-up ( 7 14 day ) period , total duration study participation subject approximately 8 week . During treatment period , subject admit clinical research unit day dose ( Day 1 ) remain completion last assessment Day 20 . All subject receive Day 1 , 6 milligram ( mg ) bolus retosiban 5 minute ( min ) , follow 6 mg/hour ( hr ) infusion 12 hr . On Day 2 , washout day occur . On Days 3-17 , subject receive EFZ 600 mg daily evening . On Day 18 , subject receive 6 mg bolus retosiban 5 min , follow 6 mg/hr infusion 12 hr plus 600 mg dose EFZ .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics , Safety Tolerability Retosiban ( GSK221149 ) When Dosed With Efavirenz ( EFZ )</brief_title>
	<detailed_description />
	<mesh_term>Obstetric Labor , Premature</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Male/females age 18 45 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator consultation GlaxoSmithKline ( GSK ) Medical Monitor agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; =50 kilogram ( kg ) body mass index within range 1929.9 kg/m^2 . A female subject eligible participate : Childbearing potential negative pregnancy test determine serum human chorionic gonadotrophin ( hCG ) test screen prior dosing ; AND Agrees use contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception followup visit ; OR samesex partner , prefer usual lifestyle . Capable give write informed consent , include compliance requirement restriction list consent form Alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin &lt; =1.5 x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Based average correct QT interval ( QTc ) value triplicate electrocardiogram obtain brief recording period : QTc &lt; 450 millisecond ( msec ) ; QTc &lt; 480 msec subject Bundle Branch Block . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study define : For United States ( US ) sit : average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 gram alcohol : 12 ounce ( 360 milliliter [ mL ] ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Has active suicidal plan/intent active suicidal thought past 6 month . Has history suicide attempt last 2 year 1 lifetime suicide attempt . Subjects history seizure exclude trial . Subjects history severe serious psychiatric disease require hospitalization , history social ideation attempt , ongoing psychiatric treatment exclude study . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . A positive prestudy drug/alcohol screen . A positive test Human Immunodeficiency Virus ( HIV ) antibody . Pregnant female determine positive serum hCG test screen prior dosing . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Lactating female . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Retosiban , Efavirenz , Induction</keyword>
</DOC>